Keros Therapeutics (NASDAQ:KROS) Trading Down 5.7% After Analyst Downgrade

Keros Therapeutics, Inc. (NASDAQ:KROS) traded down 5.7% on Tuesday after Oppenheimer lowered their price target on the stock from $102.00 to $63.00. Oppenheimer currently has an outperform rating on the stock. Keros Therapeutics traded as low as $18.12 and last traded at $18.32. 350,670 shares traded hands during mid-day trading, a decline of 24% from the average session volume of 463,453 shares. The stock had previously closed at $19.42.

A number of other equities analysts have also recently weighed in on the stock. Guggenheim cut shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research note on Friday, November 22nd. Bank of America reduced their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. BTIG Research downgraded shares of Keros Therapeutics from a “buy” rating to a “neutral” rating in a research note on Thursday, December 12th. Finally, Scotiabank reduced their price objective on Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating on the stock in a research note on Friday. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $81.33.

Hedge Funds Weigh In On Keros Therapeutics

Hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in Keros Therapeutics in the second quarter valued at $532,000. Assenagon Asset Management S.A. acquired a new stake in shares of Keros Therapeutics in the second quarter valued at about $1,118,000. Bank of New York Mellon Corp raised its stake in shares of Keros Therapeutics by 18.8% during the second quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock valued at $5,410,000 after purchasing an additional 18,755 shares during the period. Rhumbline Advisers boosted its position in Keros Therapeutics by 20.6% in the 2nd quarter. Rhumbline Advisers now owns 41,638 shares of the company’s stock valued at $1,903,000 after buying an additional 7,111 shares during the last quarter. Finally, Arizona State Retirement System boosted its holdings in Keros Therapeutics by 16.3% in the second quarter. Arizona State Retirement System now owns 8,077 shares of the company’s stock valued at $369,000 after purchasing an additional 1,130 shares during the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

Keros Therapeutics Stock Down 7.1 %

The business’s 50 day moving average is $58.29 and its 200-day moving average is $52.50. The firm has a market cap of $731.15 million, a P/E ratio of -3.48 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.28) by ($0.13). Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm had revenue of $0.39 million for the quarter. During the same quarter in the prior year, the company posted ($1.33) earnings per share. The company’s quarterly revenue was up 4750.0% on a year-over-year basis. As a group, equities analysts predict that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.